Spyre Therapeutics, Inc. Stock price

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
37.93 USD +2.51% Intraday chart for Spyre Therapeutics, Inc. -4.84% +76.25%
Sales 2024 * 6.82M Sales 2025 * 5.17M Capitalization 1.37B
Net income 2024 * -169M Net income 2025 * -167M EV / Sales 2024 * 108 x
Net cash position 2024 * 638M Net cash position 2025 * 333M EV / Sales 2025 * 201 x
P/E ratio 2024 *
-10.3 x
P/E ratio 2025 *
-12.8 x
Employees 30
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.45%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Spyre Therapeutics, Inc.

1 day+2.51%
1 week-4.84%
Current month+38.23%
1 month+45.33%
3 months+85.02%
6 months+230.98%
Current year+76.25%
More quotes
1 week
36.39
Extreme 36.39
43.00
1 month
28.48
Extreme 28.48
47.97
Current year
18.54
Extreme 18.54
47.97
1 year
2.66
Extreme 2.66
47.97
3 years
2.66
Extreme 2.66
217.00
5 years
2.66
Extreme 2.66
284.50
10 years
2.66
Extreme 2.66
318.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 34 23-06-21
Director of Finance/CFO 47 23-08-31
Chief Tech/Sci/R&D Officer - Nov. 26
Members of the board TitleAgeSince
Director/Board Member 38 23-06-21
Chairman 60 15-05-31
Director/Board Member 51 Nov. 26
More insiders
Date Price Change Volume
24-03-28 37.93 +2.51% 951,529
24-03-27 37 -1.62% 573,502
24-03-26 37.61 -2.26% 327,872
24-03-25 38.48 -6.60% 456,371
24-03-22 41.2 +3.36% 302,065

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
37.93 USD
Average target price
40 USD
Spread / Average Target
+5.46%
Consensus
  1. Stock
  2. Equities
  3. Stock Spyre Therapeutics, Inc. - Nasdaq